Welcome to the Starpharma investor centre.Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
Latest News & Announcements
New Australian site opening for DEP® trials
Jul 9th, 2020
Starpharma today announced the opening of a new trial site for the phase 2 DEP® irinotecan trial, at the Kinghorn Cancer Centre in Sydney. The DEP® irinotecan trial is also being conducted at multiple leading UK cancer centres including The Christie, The Royal Marsden, Newcastle Freeman Hospital, and The Beatson West of Scotland Cancer Centre. The Kinghorn Cancer Centre will also be opened shortly as an additional site for the phase 2 DEP® cabazitaxel trial.
Read More
DEP irinotecan boosts immuno-oncology in colon cancer models
Jun 29th, 2020
Starpharma today announced its SN-38 nanoparticle, DEP® irinotecan in combination with an immuno-oncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and significant survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC model.
Read More
Multiple DEP® products showcased at AACR 2020
Jun 23rd, 2020
Starpharma today announced that five posters featuring products based on Starpharma’s DEP® platform have been presented at the AACR (American Association for Cancer Research) Annual Meeting. The AACR Annual Meeting brings together leading cancer research and medicine from institutions all over the world and is an important forum for both raising product awareness and commercial interactions.
Read More
Starpharma to present at OTCQX Virtual Investor Conference
Jun 18th, 2020
Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 18 June 2020 (US ET) as part of OTCQX’s Virtual Investor Conference for Global Mid-cap and Large-cap Companies. The conference is primarily attended by US-based retail investors, as well as advisors.
Read More
Reports & Presentations
Click here for financial reports archive
Interim Report and Half-Year Financial Results
Feb 24th, 2020
Starpharma today released its interim report and financial results for the half-year ended 31 December 2019.
Read More
Starpharma Interim Report and Half-Year Financial Results
Feb 27th, 2019
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its interim report and financial results for the half-year ended 31 December 2018.
Read More
Shareholder Update January 2019
Jan 17th, 2019
In this issue:
>> FDA requests further data for VivaGel® BV approval in the US
>> Launch of VivaGel® BV in multiple territories
>> VivaGel® BV licensed to ITF Pharma in the US
>> VivaGel® condom approved in Japan
>> Clinical trials for internal DEP® products progressing well
>> Patent published for AstraZeneca-DEP® drugs: DEP® Bcl2/xL inhibitors show compelling efficacy & synergy in combination
>> DEP® docetaxel & DEP® cabazitaxel outperformed both gemcitabine & Abraxane®
>> SPL7013 eye drops for viral conjunctivitis
>> Partnering activities
>> Macquarie initiates coverage of Starpharma
>> Outlook
Download: Shareholder Update January 2019 (pdf file, 557kb)
Read More
Starpharma Investor Presentation for Citi Conference
Oct 17th, 2018
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) will today participate in Citi's 10th Annual Australian and New Zealand Investment Conference in Sydney.
Read More
Annual report and full year financial results
Aug 21st, 2018
Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2018.
Read More
VivaGel® BV - Product Information and Independent Market Research
Apr 30th, 2018
VivaGel® BV - Product Information and Independent Market Research
Read More
Starpharma to present at OTCQX Virtual Investor Conference
Apr 11th, 2018
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday 12 April 2018 at 10:30am (US ET time).
Read More
AGM Chairman’s address and CEO presentation
Nov 29th, 2017
Chairman’s address and the CEO’s presentation to the 2017 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).
Read More
Starpharma annual report and full year financial results
Aug 28th, 2017
Melbourne, Australia; 28 August 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its annual report and financial results for the year ended 30 June 2017.
Sale of Agrochemicals Business Investor Presentation
Jun 14th, 2017
Melbourne, Australia; 14 June 2017: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), will be holding an investor conference call today at 11am (AEST) to discuss the sale of its Agrochemicals business to Agrium Inc., for $35 million. A presentation featuring further information on the transaction is available.
Read MoreIn the Media
Click here for more In the Media
Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business
Jul 1st, 2018
|
Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler about how the company has taken VivaGel® BV from discovery to market and developed commercial products with its proprietary dendrimer technology platform. |
To listen to the podcast, click here.
Read More
Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider
Jul 1st, 2018
Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.
Read More
Starpharma announces DEP cabazitaxel Phase 1/2 Trial
Jan 31st, 2018
Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals.
Read More
AstraZeneca plans to make better use of Australia’s innovation
Jan 23rd, 2018
|
The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic. |
Starpharma rockets on cancer drug hope
Sep 23rd, 2017
The Herald Sun noted strong investor interest and support for Starpharma regarding its positive phase 1 DEP® docetaxel trial and that no neutropenia was reported in any patients.
Read More
Starpharma featured on Sky Business News
Aug 28th, 2017
|
Starpharma CEO Dr Jackie Fairly was interviewed on Sky Business News’ Ticky following the company’s successful Phase 3 trial results for VivaGel® BV for the treatment of recurrent bacterial vaginosis. Dr Fairley discussed the commercial significance of the announcement and liaising with the US FDA to bring the product to market. |
To watch the interview, click here.
Read More
Starpharma CEO on Finance News Network
Aug 24th, 2017
|
Finance News Network featured Dr Jackie Fairley as she discussed the company’s VivaGel® BV Phase 3 results for recurrent bacterial vaginosis, the company's sale of its agrochemical business for $35M, and progress with its DEP® drug delivery programs (both internal and external). |
To watch the interview, click here.
Read More
Seeking Alpha covers Starpharma
Aug 11th, 2017
|
Online stock market insights and research publication Seeking Alpha covered Starpharma’s Phase 3 results for VivaGel® BV for the treatment of recurrent bacterial vaginosis and noted the “substantial upside” of the announcement. To view the article, click here. |
Starpharma and Monash awarded STEM+ Business fellowships
Aug 10th, 2017
|
Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform. To view the article, click here. |
Hope is on the way for one of the world’s most common sexual problems
Aug 9th, 2017
Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age.
Go to article (external link)
Read More
Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis
Aug 9th, 2017
Biotech trade publication noted Starpharma expects to file an NDA for VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) with the US FDA following the positive results of the Phase 3 trials.
Read More
Biotech clinical trials a star performer
Aug 6th, 2017
Herald Sun covered the investor interest in Starpharma following the positive results of the company’s VivaGel® BV Phase 3 clinical trials for the prevention of recurrent bacterial vaginosis (rBV). Starpharma CEO Dr Jackie Fairley noted VivaGel® BV demonstrated sustained benefits for patients three months after their initial treatment, positioning the company to unlock a multi-million dollar global market.
Go to article (external link)
Read More
Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base
Jun 23rd, 2017
The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.
Read More
Starpharma featured on Business IQ, Sky Business News
Jun 20th, 2017
Starpharma CEO Dr Jackie Fairley was interviewed on Sky Business News where she spoke to Business IQ host James Daggar-Nickson about dendrimer technologies and how the company develops products for a wide range of applications using the platform technology. Dr Fairley also discussed Australian innovation and the company's recent sale of its agrochemical business to global agricultural product giant Agrium.
Read More
Finance News Network: Starpharma sells Agrochemicals business for $35M
Jun 14th, 2017
Finance News Network noted Starpharma’s transaction to sell Starpharma Agrochemicals to Agrium Inc. for A$35M in cash consideration. The piece added that cash proceeds from the sale will allow Starpharma to focus on its core pharmaceutical development portfolio.
Go to the article (external link)
Read More
Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land
Jun 14th, 2017
The sale of Starpharma’s agrochemical business was covered in The Land, with the article highlighting the innovation behind the Priostar® technology and how Agrium saw the acquisition as a strategic fit for their product portfolio.
Read More
Starpharma featured on Ticky on Sky Business News
Apr 20th, 2017
Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.
Go to the article (external link)
Read More
Melbourne-based company develops world's first anti-viral condom
Apr 12th, 2017
The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.
Go to the article (external link)
Read More
Starpharma VivaGel® BV gets FDA fast track
Jan 13th, 2017
The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.
Go to the article (external link)
Read More